Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf® Monitoring

Overview

About this study

The purpose of this study is to determine the safety of Mycophenolate Mofetil withdrawl in kidney transplant recipients aged 55 years or older at the time of transplantation compared to standard of care. MMF will be withdrawn by 10 months after kidney trasnplantation with all patients followed for 24 months. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

Time of Transplant Inclusion Criteria.

  • Solitary kidney transplant recipient >55 years of age—first or second transplants.
  • No other solid organ transplant though recipients of autologous stem cell transplants are eligible.
  • HIV negative.

Time of Transplant Inclusion Criteria.

  • Solitary kidney transplant recipient >55 years of age—first or second transplants.
  • No other solid organ transplant though recipients of autologous stem cell transplants are eligible.
  • HIV negative.

Time of Transplant Exclusion Criteria.

  • DSA MFI > 500.
  • cPRA> 80% (based on MFI > 2000).
  • Prior treatment with MMF or need for MMF therapy (To treat a disease including their primary renal disease).
  • Has a history of an underlying clinically significant acute or chronic medical condition or physical examination findings which, in the opinion of the investigator, would make study participation not be in the participants best. interest (e.g., compromise the well-being) or that could prevent, or limit the protocol-specified assessment.

4-month exclusion criteria (i.e. patients not suitable for MMF withdrawal).

  • Acute rejection episode either clinical or on biopsy (greater than borderline). Subjects must not experience any type of rejection episodes from the time of transplant and must not show any signs of rejection (Cellular or Antibody mediated rejection, excluding borderline) at their 4-month standard of care biopsy Subjects experiencing rejection will not be eligible for randomization and MMF withdrawal.
  • De novo DSA.

Subjects who do not meet the inclusion criteria to move forward with randomization for MMF withdrawal will continue in the study and will follow all standard of care protocol study visits and related procedures, excluding the blood collection of Subject samples obtained for TruGraf® and Viracor TRAC® assays.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/25/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mark Stegall, M.D.

Contact us for the latest status

Contact information:

Mollie Luhman

(507) 266-2812

Luhman.Mollie@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20571938

Mayo Clinic Footer